Mesoblast Reports Strong Half-Year Revenue Growth from Ryoncil and Secures $125M Non-Dilutive Credit Facility

summarizeSummary

Mesoblast reported a significant increase in revenue driven by Ryoncil sales and a reduced net loss for the half-year, bolstered by a new $125 million non-dilutive credit facility that improved liquidity and debt structure.

check_boxKey Events

• Significant Revenue Growth

  Total revenues surged to $51.3 million for the six months ended December 31, 2025, up from $3.2 million in the prior year, primarily due to $48.7 million in net product sales from Ryoncil®.

• Reduced Net Loss

  The company's net loss decreased to $40.2 million for the period, an improvement from a $47.9 million loss in the same period last year.

• New Non-Dilutive Credit Facility Secured

  Mesoblast entered into a $125.0 million five-year non-dilutive credit-line facility, drawing $75.0 million to repay existing senior debt and partially reduce another loan, enhancing liquidity.

• Positive Going Concern Statement

  Management expects existing cash and Ryoncil sales to be sufficient to fund operating cash usage for the next twelve months.

auto_awesomeAnalysis

Mesoblast Limited reported a significant improvement in its financial performance for the six months ended December 31, 2025, primarily driven by the successful commercialization of its Ryoncil® product. The company achieved $48.7 million in net product sales from Ryoncil, a substantial increase from zero in the prior corresponding period, leading to total revenues of $51.3 million. This strong revenue growth contributed to a reduction in net loss to $40.2 million, down from $47.9 million year-over-year. Furthermore, Mesoblast secured a new $125.0 million five-year non-dilutive credit-line facility, with $75.0 million already drawn. These proceeds were used to fully repay an existing senior secured loan with Oaktree Capital Management and partially repay a NovaQuest facility, significantly improving the company's liquidity and extending its cash runway. While net cash outflows from operating activities increased, the company's management explicitly stated that existing cash and Ryoncil sales are expected to be sufficient to fund operations for the next twelve months, addressing going concern considerations. Warrants to purchase 3,225,756 shares were granted as part of the new credit facility, representing potential future dilution.